Lawrence Steinman has bought stock on 2 days since Dec 2023
Director at Pasithea Therapeutics Corp., and 1 other company
SEC CIK 0001132679 · Filings on SEC.gov ↗
Lawrence Steinman's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
Every filing
2 filings since Dec 2023, newest first
About Lawrence Steinman
Prof. Lawrence Steinman, MD, PhD is the Executive Chairman and Co-Founder of Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company focused on developing treatments for central nervous system disorders, particularly multiple sclerosis.( He joined the board in August 2020 and has been instrumental in advancing the company's PAS-002 program, a DNA plasmid vaccine targeting GlialCAM for MS treatment, leveraging his pioneering research on molecular mimicry in MS pathogenesis.(
A renowned neurologist, Steinman is a professor of neurology, neurological sciences, pediatrics, and genetics at Stanford University School of Medicine, where he founded the Steinman Laboratory dedicated to autoimmune diseases like MS and neuromyelitis optica.( His career highlights include senior authorship of the 1992 Nature paper on integrins leading to Tysabri, a blockbuster MS drug; co-founding companies such as Atreca, BioAtla, Tolerion, Neurocrine Biosciences, and others; serving on boards like Centocor (1989-1998) and BioAtla; holding 41 patents; and receiving awards like the 2023 Pioneer in Medicine Award, Dystel Prize, and Javits Neuroscience Investigator Award. He is a member of the National Academy of Sciences and National Academy of Medicine.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.